Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The European Association for the Study of Diabetes (EASD) has awarded Prof Anna Gloyn the 2014 Minkowski Prize in recognition of her research contributing to the advancement of knowledge concerning diabetes.

Logo of the European Association for the Study of Diabetes

As the recipient of this prestigious award, Prof Gloyn delivered the 49th Minkowski lecture at the 50th EASD Annual Meeting in Vienna on Thursday 18th September 2014. The title of her lecture was ‘Unravelling causal mechanisms in diabetes pathogenesis’. Her lecture can be viewed on the ESAD website.

The consistent focus of Anna’s work has been the study of naturally occurring mutations that cause or are associated with increased risk of diabetes. Although a basic scientist, her work is highly translational. Anna’s work describing a novel genetic cause of neonatal diabetes revolutionised how patients with this condition are treated, whilst her recent work on biomarkers for HNF1A-MODY has provided a cost effective way of prioritising patients for genetic testing. Anna has also used human genetics to demonstrate the interplay between pathways involved in cell growth and metabolism. Most recently, she has led on international efforts to elucidate the molecular mechanisms for genetic variants associated with type 2 diabetes risk and influencing metabolic traits.

We want to hear about your news!

Publishing a paper? Just won an award? Get in touch with communications@rdm.ox.ac.uk

 

Similar stories

New heart disease calculator could save lives by identifying high-risk patients missed by current tools

Collaborative research, led from NDPCHS and published today in Nature Medicine, has developed a new tool called QR4 that more accurately predicts an individual's 10-year risk of cardiovascular diseases, like heart disease and stroke, particularly identifying high-risk patients that current prediction tools miss.